Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina's acquisition of cancer-test developer Grail while the Federal Trade Commission fights to unwind the deal.
The groups filed 14 amicus briefs Monday urging the U.S. 5th Circuit Court of Appeals to reverse an FTC order that would have Illumina undo the $7.1 billion Grail deal over concerns that it stifles competition.
Thirty-four Republican lawmakers touted Grail's early screening test, which can detect more than 50 types of cancers through a single blood draw.
And activist investor Carl Icahn, who holds a 1.4% stake in Illumina, launched a proxy fight with the company over the Grail deal.
Icahn's opposition stemmed from Illumina's decision to close the acquisition without first gaining approval from antitrust regulators.
Persons:
Illumina, Carl Icahn, Francis deSouza
Organizations:
Federal Trade Commission, U.S, FTC, Food and Drug Administration, European Commission
Locations:
San Diego, Alaska , Arkansas, Georgia , Idaho , Indiana , Iowa , Kentucky, Louisiana , Nebraska, South Carolina , Utah, Virginia, Illumina